Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

NCT06651281 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1380

Enrollment

INDUSTRY

Sponsor class

Conditions

Crohn Disease
Colitis, Ulcerative

Interventions

DRUG: Tulisokibart
DRUG: Placebo to tulisokibart

Sponsor

Merck Sharp & Dohme LLC